Treatment Updates for Type 1 Autoimmune Pancreatitis and IgG4-Related Diseases
SMART-MD Journal of Precision Medicine · 2026
DOI: 10.69734/8p34ma30 ↗Kurz gefasst
Fachartikel in der Zeitschrift SMART-MD Journal of Precision Medicine, 2026. Verfasst von Yasmin Hernandez-Barco und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Type 1 autoimmune pancreatitis (AIP) is the pancreatic manifestation of IgG4-related disease. Glucocorticoids induce remission but relapse is common and toxicity limits maintenance use. Conventional immunosuppressants have a modest steroid-sparing role when B-cell therapy is unavailable. Rituximab is effective but off-label. Inebilizumab, a CD19-depleting antibody, is FDA-approved for adult IgG4-RD after MITIGATE showed an 87% reduction in adjudicated flares. Obexelimab, a nondepleting CD19/FcγRIIb inhibitor, reduced flare risk and glucocorticoid exposure in INDIGO; a BLA is under review. BTK inhibitors, FcRn blockade, and cellular therapies remain investigational. Treatment should be guided by organ burden, relapse risk, and comorbidity rather than a default steroid course for every patient.
Zitieren
APA
Hernandez-Barco, Y., & Perugino, C. A. (2026). Treatment Updates for Type 1 Autoimmune Pancreatitis and IgG4-Related Diseases. SMART-MD Journal of Precision Medicine. https://doi.org/10.69734/8p34ma30
Vancouver
Hernandez-Barco Y, Perugino CA. Treatment Updates for Type 1 Autoimmune Pancreatitis and IgG4-Related Diseases. SMART-MD Journal of Precision Medicine. 2026. doi:10.69734/8p34ma30
BibTeX
@article{HernandezBarco2026,
author = {Hernandez-Barco, Yasmin and Perugino, Cory A.},
title = {Treatment Updates for Type 1 Autoimmune Pancreatitis and IgG4-Related Diseases},
journal = {SMART-MD Journal of Precision Medicine},
year = {2026},
doi = {10.69734/8p34ma30}
}
EUVIMED